Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery.
暂无分享,去创建一个
[1] P. Kesharwani,et al. Effect of surface capping on targeting potential of folate decorated poly (propylene imine) dendrimers , 2015, Drug development and industrial pharmacy.
[2] Yi Jin,et al. Preparation and in vitro characterization of pluronic-attached polyamidoamine dendrimers for drug delivery , 2015, Drug development and industrial pharmacy.
[3] Yanyan Jiang,et al. Development of biodegradable polymeric implants of RGD-modified PEG-PAMAM-DOX conjugates for long-term intratumoral release , 2015, Drug delivery.
[4] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[5] S. Kannan,et al. Emerging concepts in dendrimer‐based nanomedicine: from design principles to clinical applications , 2014, Journal of internal medicine.
[6] N. K. Jain,et al. Formulation development and in vitro-in vivo assessment of the fourth-generation PPI dendrimer as a cancer-targeting vector. , 2014, Nanomedicine.
[7] T. Higashi,et al. Preparation and evaluation of polyamidoamine dendrimer conjugate with glucuronylglucosyl-β-cyclodextrin (G3) as a novel carrier for siRNA , 2014, Journal of drug targeting.
[8] Chao Chen,et al. Targeted delivery of Dicer-substrate siRNAs using a dual targeting peptide decorated dendrimer delivery system. , 2014, Nanomedicine : nanotechnology, biology, and medicine.
[9] Tamer Refaat,et al. Passive targeting of nanoparticles to cancer: A comprehensive review of the literature. , 2014, Molecular and clinical oncology.
[10] Mingwu Shen,et al. Multifunctional lactobionic acid-modified dendrimers for targeted drug delivery to liver cancer cells: investigating the role played by PEG spacer. , 2014, ACS applied materials & interfaces.
[11] Deep Pooja,et al. Dendrimer-TPGS mixed micelles for enhanced solubility and cellular toxicity of taxanes. , 2014, Colloids and surfaces. B, Biointerfaces.
[12] T. Niidome,et al. Hydrophobic cavity formed by oligopeptide for doxorubicin delivery based on dendritic poly(L-lysine) , 2014, Journal of biomaterials science. Polymer edition.
[13] X. Li,et al. PEGylated PAMAM dendrimer-doxorubicin conjugate-hybridized gold nanorod for combined photothermal-chemotherapy. , 2014, Biomaterials.
[14] Keerti Jain,et al. Dendronized nanoconjugates of lysine and folate for treatment of cancer. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[15] J. Kleeff,et al. Effect of gemcitabine and retinoic acid loaded PAMAM dendrimer-coated magnetic nanoparticles on pancreatic cancer and stellate cell lines. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[16] N. K. Jain,et al. Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer. , 2014, Biomaterials.
[17] Jing Zhao,et al. Cell‐Penetrable Lysine Dendrimers for Anti‐Cancer Drug Delivery: Synthesis and Preliminary Biological Evaluation , 2014, Archiv der Pharmazie.
[18] Yu Wang,et al. Fluorinated poly(propylenimine) dendrimers as gene vectors. , 2014, Biomaterials.
[19] Vladimir P Torchilin,et al. Barriers to drug delivery in solid tumors , 2014, Tissue barriers.
[20] C. Tros de Ilarduya,et al. Efficient targeted gene delivery by a novel PAMAM/DNA dendriplex coated with hyaluronic acid. , 2014, Nanomedicine.
[21] D. Owen,et al. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[22] Z. Duan,et al. Nanodelivery systems for nucleic acid therapeutics in drug resistant tumors. , 2014, Molecular pharmaceutics.
[23] Keerti Jain,et al. Dendrimer as nanocarrier for drug delivery , 2014 .
[24] P. Sætrom,et al. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo , 2014, Hepatology.
[25] S. Ganta,et al. Role of integrated cancer nanomedicine in overcoming drug resistance. , 2013, Advanced drug delivery reviews.
[26] H. Gérard,et al. Dendrimer-enabled DNA delivery and transformation of Chlamydia pneumoniae. , 2013, Nanomedicine : nanotechnology, biology, and medicine.
[27] T. Minko,et al. Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: An Optimal Delivery of siRNA and Anticancer Drug , 2013, Clinical Cancer Research.
[28] D. Ma,et al. Photoenhanced gene transfection by a star-shaped polymer consisting of a porphyrin core and poly(L-lysine) dendron arms. , 2013, Macromolecular bioscience.
[29] Jian-tao Lin,et al. New cyclodextrin derivative containing poly(L-lysine) dendrons for gene and drug co-delivery. , 2013, Journal of colloid and interface science.
[30] Dzmitry G. Shcharbin,et al. Nanomaterials in stroke treatment: perspectives. , 2013, Stroke.
[31] R. Tekade,et al. Cancer targeting potential of folate targeted nanocarrier under comparative influence of tretinoin and dexamethasone. , 2013, Current drug delivery.
[32] Jintian Tang,et al. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. , 2013, Advanced drug delivery reviews.
[33] Scott H. Medina,et al. Enzyme-activated nanoconjugates for tunable release of doxorubicin in hepatic cancer cells. , 2013, Biomaterials.
[34] R. Tekade,et al. The effect of polyethylene glycol spacer chain length on the tumor-targeting potential of folate-modified PPI dendrimers , 2013, Journal of Nanoparticle Research.
[35] M. Zloh,et al. Cationic poly-L-lysine dendrimer complexes doxorubicin and delays tumor growth in vitro and in vivo. , 2013, ACS nano.
[36] Michael Riediker,et al. Therapeutic nanoparticles in clinics and under clinical evaluation. , 2013, Nanomedicine.
[37] J. Hsieh,et al. Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry. , 2013, Molecular pharmaceutics.
[38] Kui Luo,et al. Dendronized heparin-doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy. , 2013, Biomaterials.
[39] R. Dinarvand,et al. A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis , 2013, Cancer Chemotherapy and Pharmacology.
[40] Jianru Xiao,et al. Reducing cytotoxicity while improving anti-cancer drug loading capacity of polypropylenimine dendrimers by surface acetylation. , 2012, Acta biomaterialia.
[41] N. K. Jain,et al. Synthesis, characterization and brain targeting potential of paclitaxel loaded thiamine-PPI nanoconjugates , 2012, Journal of drug targeting.
[42] Prashant Kesharwani,et al. Carbon nanotube exploration in cancer cell lines. , 2012, Drug discovery today.
[43] N. K. Jain,et al. Spectrophotometric estimation of paclitaxel , 2011 .
[44] N. K. Jain,et al. The treatment of Glioblastoma Xenografts by surfactant conjugated dendritic nanoconjugates. , 2011, Biomaterials.
[45] L. Kaminskas,et al. Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. , 2011, Nanomedicine.
[46] Mansoor Amiji,et al. Combinatorial-designed multifunctional polymeric nanosystems for tumor-targeted therapeutic delivery. , 2011, Accounts of chemical research.
[47] N. K. Jain,et al. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. , 2011, Nanomedicine : nanotechnology, biology, and medicine.
[48] Anupama Sharma,et al. Surface modified dendrimers: synthesis and characterization for cancer targeted drug delivery. , 2011, Bioorganic & medicinal chemistry.
[49] Jian-ping Xu,et al. Polyamidoamine dendrimers surface-engineered with biomimetic phosphorylcholine as potential drug delivery carriers. , 2011, Colloids and surfaces. B, Biointerfaces.
[50] Thommey P. Thomas,et al. Polyvalent saccharide-functionalized generation 3 poly(amidoamine) dendrimer-methotrexate conjugate as a potential anticancer agent. , 2011, Bioorganic & medicinal chemistry.
[51] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[52] Min Zhang,et al. Multifunctional Triblock Nanocarrier (PAMAM-PEG-PLL) for the Efficient Intracellular siRNA Delivery and Gene Silencing , 2011, ACS nano.
[53] S. Valiyaveettil,et al. Active targeting of cancer cells using folic acid-conjugated platinum nanoparticles. , 2010, Nanoscale.
[54] G. Drossopoulou,et al. Synthesis of a folate functionalized PEGylated poly(propylene imine) dendrimer as prospective targeted drug delivery system. , 2010, Bioorganic & medicinal chemistry letters.
[55] W. A. Yeudall,et al. Dendrimer-triglycine-EGF nanoparticles for tumor imaging and targeted nucleic acid and drug delivery. , 2010, Oral oncology.
[56] R. Konwar,et al. Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells. , 2010, International journal of pharmaceutics.
[57] T. Minko,et al. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[58] B. Nanjwade,et al. Dendrimers: emerging polymers for drug-delivery systems. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[59] N. K. Jain,et al. Dextran conjugated dendritic nanoconstructs as potential vectors for anti-cancer agent. , 2009, Biomaterials.
[60] N. K. Jain,et al. Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics , 2009, Journal of microencapsulation.
[61] Narendra Kumar Jain,et al. Dendrimers in oncology: an expanding horizon. , 2009, Chemical reviews.
[62] T. Xu,et al. Targeting cancer cells with biotin-dendrimer conjugates. , 2009, European journal of medicinal chemistry.
[63] Daniel G. Anderson,et al. Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.
[64] M. Ogris,et al. Oligoethylenimine-grafted polypropylenimine dendrimers as degradable and biocompatible synthetic vectors for gene delivery. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[65] Dong-Eun Kim,et al. Evaluation of generations 2, 3 and 4 arginine modified PAMAM dendrimers for gene delivery. , 2008, International journal of pharmaceutics.
[66] S. Betigeri,et al. Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. , 2008, Bioconjugate chemistry.
[67] J. Karp,et al. Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .
[68] Michihiro Nakamura,et al. Nanomedicine for drug delivery and imaging: A promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles , 2007, International journal of cancer.
[69] P. Erba,et al. Towards the use of nanoparticles in cancer therapy and imaging. , 2007, Drug news & perspectives.
[70] J. Rossi,et al. RNAi therapeutics: principles, prospects and challenges. , 2007, Advanced drug delivery reviews.
[71] E. Simanek,et al. Dendrimers as drug delivery vehicles: non-covalent interactions of bioactive compounds with dendrimers. , 2007, Polymer international.
[72] D. Tomalia,et al. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. , 2007, Biochemical Society transactions.
[73] T. Mandal,et al. Engineered nanoparticles in cancer therapy. , 2007, Recent patents on drug delivery & formulation.
[74] H. Maeda,et al. Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.
[75] Shi Yunyu,et al. Dendrimers as potential drug carriers. Part II. Prolonged delivery of ketoprofen by in vitro and in vivo studies. , 2006, European journal of medicinal chemistry.
[76] T. Wu,et al. Prospects of RNA interference therapy for cancer , 2006, Gene Therapy.
[77] M. Dewhirst,et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. , 2006, Journal of the National Cancer Institute.
[78] R. Griffey,et al. Improving RNA interference in mammalian cells by 4'-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2'-O-alkyl modifications. , 2006, Journal of medicinal chemistry.
[79] R. Duncan,et al. Dendrimer biocompatibility and toxicity. , 2005, Advanced drug delivery reviews.
[80] Anil K Patri,et al. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. , 2005, Advanced drug delivery reviews.
[81] H. Hui,et al. Thermo- and pH-sensitive dendrimer derivatives with a shell of poly(N,N-dimethylaminoethyl methacrylate) and study of their controlled drug release behavior , 2005 .
[82] A. Schätzlein,et al. Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. , 2005, Cancer research.
[83] L. Bohm,et al. Evaluation of cisplatin and a novel platinum polymer conjugate for drug toxicity and drug distribution in mice , 2005, Anti-cancer drugs.
[84] D. Tomalia. Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry , 2005 .
[85] F. Hirayama,et al. Enhancing effects of galactosylated dendrimer/alpha-cyclodextrin conjugates on gene transfer efficiency. , 2005, Biological & pharmaceutical bulletin.
[86] E. W. Meijer,et al. Multivalency in the gas phase: the study of dendritic aggregates by mass spectrometry. , 2004, Angewandte Chemie.
[87] S. Sahoo,et al. Nanotech approaches to drug delivery and imaging. , 2003, Drug discovery today.
[88] Manouchehr Mirshahi,et al. Efficacy of dendrimer‐mediated angiostatin and TIMP‐2 gene delivery on inhibition of tumor growth and angiogenesis: In vitro and in vivo studies , 2003, International journal of cancer.
[89] S. Jain,et al. A PEGylated dendritic nanoparticulate carrier of fluorouracil. , 2003, International journal of pharmaceutics.
[90] P. Couvreur,et al. Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.
[91] Thommey P. Thomas,et al. Design and Function of a Dendrimer-Based Therapeutic Nanodevice Targeted to Tumor Cells Through the Folate Receptor , 2002, Pharmaceutical Research.
[92] Takuro Niidome,et al. In vitro gene transfection using dendritic poly(L-lysine). , 2002, Bioconjugate chemistry.
[93] H. Maeda,et al. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[94] F. Hirayama,et al. Enhancement of gene expression by polyamidoamine dendrimer conjugates with alpha-, beta-, and gamma-cyclodextrins. , 2001, Bioconjugate chemistry.
[95] J. Fréchet,et al. Fast and convenient divergent synthesis of aliphatic ester dendrimers by anhydride coupling. , 2001, Journal of the American Chemical Society.
[96] H. Maeda. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.
[97] M. Rymaszewski,et al. Intravascular and endobronchial DNA delivery to murine lung tissue using a novel, nonviral vector. , 2000, Human gene therapy.
[98] M. Milella,et al. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study. , 2000, American journal of clinical oncology.
[99] H. Maeda,et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[100] J. Fréchet,et al. Designing dendrimers for drug delivery. , 1999, Pharmaceutical science & technology today.
[101] R K Jain,et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.
[102] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[103] Yanan Liu,et al. Multifunctional polyamidoamine-modified selenium nanoparticles dual-delivering siRNA and cisplatin to A549/DDP cells for reversal multidrug resistance. , 2015, Acta biomaterialia.
[104] Xue Ying,et al. PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. , 2011, Biomaterials.
[105] Huixin He,et al. Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes. , 2011, Current drug delivery.
[106] Robert Blumenthal,et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. , 2009, Critical reviews in therapeutic drug carrier systems.
[107] Lee Josephson,et al. Current state and future applications of active targeting in malignancies using superparamagnetic iron oxide nanoparticles. , 2009, Cancer biomarkers : section A of Disease markers.
[108] E. Bárdi,et al. Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer , 2008, Pathology & Oncology Research.
[109] S. Parveen,et al. Polymeric nanoparticles for cancer therapy. , 2008, Journal of drug targeting.
[110] J. Fréchet,et al. Dendrimers and dendritic polymers in drug delivery. , 2005, Drug discovery today.
[111] H. Maeda,et al. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. , 2003, Clinical pharmacokinetics.
[112] M. Gottesman,et al. Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.
[113] James R. Dewald,et al. A New Class of Polymers: Starburst-Dendritic Macromolecules , 1985 .